The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis
in vivo study by high-resolution magnetic resonance imaging
Roberto Corti, MD*,
Julio I. Osende, MD*,
John T. Fallon, MD, PhD*,
Valentin Fuster, MD, PhD*,
Gabor Mizsei, MSEE*,
Hani Jneid, MD*,
Samuel D. Wright, PhD ,
William F. Chaplin, PhD* and
Juan J. Badimon, PhD*,*
* Cardiovascular Biology Research Laboratory, The Cardiovascular Institute, Mount Sinai School of Medicine, New York, New York, USA
Merck & Co, Inc., Rathway, New Jersey, USA
Manuscript received April 3, 2003;
revised manuscript received August 20, 2003,
accepted August 25, 2003.
* Reprint requests and correspondence: Dr. Juan J. Badimon, Cardiovascular Biology Research Laboratory, Mount Sinai Medical School of Medicine, One Gustave Levy Place, P.O. Box 1030, New York, New York 10029, USA.
Juan.Badimon{at}mssm.edu
OBJECTIVES: We sought to investigate the anti-atherogenic effects of a selective peroxisomal proliferator-activated receptor-gamma (PPAR-gamma) agonist and simvastatin, as well as their combination, over time, in a rabbit model of experimental atherosclerosis.
BACKGROUND: The PPARs are nuclear transcription factors that control a variety of cellular functions, with the potential effects required to induce plaque regression and stabilization.
METHODS: Atherosclerosis was induced in rabbits (n = 37) by the combination of double-balloon injury and a nine-month high-cholesterol (HC) diet. The rabbits were randomized into a continued HC diet, a normal chow (NC) diet, NC plus simvastatin, NC plus PPAR-gamma agonist, and NC plus simvastatin plus PPAR-gamma agonist. All rabbits underwent magnetic resonance imaging (MRI) at randomization and after six months of treatment and were then sacrificed for histopathologic study.
RESULTS: All groups had a similar vessel wall area by MRI (8.45 ± 0.65 mm2, p = NS between groups) at randomization. Significant progression was seen in the HC diet group (15 ± 4%, p < 0.01). In the NC and NC plus PPAR-gamma agonist groups, progression was abolished (–2.5 ± 3% and –4.5 ± 5%, respectively; p = NS). The NC plus simvastatin and NC plus simvastatin plus PPAR-gamma agonist groups had significant plaque regression (–12 ± 4% [p < 0.05] and –22 ± 4% [p < 0.01], respectively). Regression was independent of plasma lipid levels. All NC groups had similar lipid profiles at the end of treatment. Histopathologic analysis of the NC groups showed a decreased macrophage content and matrix metalloproteinase activity and an increased smooth muscle cell/collagen content of lesions.
CONCLUSIONS: Our data indicate that normalization of plasma lipid levels abolishes progression of atherosclerosis. Simvastatin elicits regression of atherosclerotic lesions, and the combination simvastatin plus PPAR-gamma agonist has additive regression effects on plaque. This is paralleled by structural alterations in plaque composition, which may increase plaque stability. These observations support the beneficial effects of statins on atherosclerosis and show additional anti-atherogenic benefits of combining a PPAR-gamma agonist with simvastatin.
|
Abbreviations and Acronyms
| | COX-2 | = cyclooxygenase-2 | | HC | = high-cholesterol | | KO | = knockout | | LDL | = low-density lipoprotein | | MMP | = matrix metalloproteinase | | MRI | = magnetic resonance imaging | | NC | = normal chow | | PBS | = phosphate-buffered saline | | PPAR | = peroxisomal proliferator-activated receptor | | SMC | = smooth muscle cell | | VWA | = vessel wall area |
|
This article has been cited by other articles:
|
|
|
|
 
J. D. Miller, R. M. Weiss, K. M. Serrano, R. M. Brooks II, C. J. Berry, K. Zimmerman, S. G. Young, and D. D. Heistad
Lowering Plasma Cholesterol Levels Halts Progression of Aortic Valve Disease in Mice
Circulation,
May 26, 2009;
119(20):
2693 - 2701.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Phinikaridou, K. J. Hallock, Y. Qiao, and J. A. Hamilton
A robust rabbit model of human atherosclerosis and atherothrombosis
J. Lipid Res.,
May 1, 2009;
50(5):
787 - 797.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Mahmoudi, I. Gorenne, J. Mercer, N. Figg, T. Littlewood, and M. Bennett
Statins Use a Novel Nijmegen Breakage Syndrome-1-Dependent Pathway to Accelerate DNA Repair in Vascular Smooth Muscle Cells
Circ. Res.,
September 26, 2008;
103(7):
717 - 725.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Ibanez, G. Vilahur, G. Cimmino, W. S. Speidl, A. Pinero, B. G. Choi, M. U. Zafar, C. G. Santos-Gallego, B. Krause, L. Badimon, et al.
Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis.
J. Am. Coll. Cardiol.,
March 18, 2008;
51(11):
1104 - 1109.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X.-Q. Zhao and B. G. Brown
ApoA-I(Milano)/phospholipid complex: clinical implications of dose-response studies in rabbit atherosclerosis with intravascular ultrasound and magnetic resonance imaging.
J. Am. Coll. Cardiol.,
March 18, 2008;
51(11):
1110 - 1111.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Bauersachs, K. Hiss, D. Fraccarollo, U. Laufs, and H. Ruetten
Simvastatin improves left ventricular function after myocardial infarction in hypercholesterolemic rabbits by anti-inflammatory effects
Cardiovasc Res,
December 1, 2006;
72(3):
438 - 446.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Gilde, J.-C. Fruchart, and B. Staels
Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease
J. Am. Coll. Cardiol.,
October 27, 2006;
48(9_Suppl_A):
A24 - A32.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Wilensky, H. K. Song, and V. A. Ferrari
Role of magnetic resonance and intravascular magnetic resonance in the detection of vulnerable plaques.
J. Am. Coll. Cardiol.,
April 18, 2006;
47(8 Suppl):
C48 - C56.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Raggi, A. Taylor, Z. Fayad, D. O'Leary, S. Nissen, D. Rader, and L. J. Shaw
Atherosclerotic Plaque Imaging: Contemporary Role in Preventive Cardiology
Arch Intern Med,
November 14, 2005;
165(20):
2345 - 2353.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, Z. A. Fayad, P. R. Moreno, M. Poon, R. Corti, and J. J. Badimon
Atherothrombosis and High-Risk Plaque: Part II: Approaches by Noninvasive Computed Tomographic/Magnetic Resonance Imaging
J. Am. Coll. Cardiol.,
October 4, 2005;
46(7):
1209 - 1218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. F. Viles-Gonzalez, V. Fuster, R. Corti, C. Valdiviezo, R. Hutter, S. Corda, S. X. Anand, and J. J. Badimon
Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition--a magnetic resonance imaging study
Eur. Heart J.,
August 1, 2005;
26(15):
1557 - 1561.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Corti, V. Fuster, Z. A. Fayad, S. G. Worthley, G. Helft, W. F. Chaplin, J. Muntwyler, J. F. Viles-Gonzalez, J. Weinberger, D. A. Smith, et al.
Effects of Aggressive Versus Conventional Lipid-Lowering Therapy by Simvastatin on Human Atherosclerotic Lesions: A Prospective, Randomized, Double-Blind Trial With High-Resolution Magnetic Resonance Imaging
J. Am. Coll. Cardiol.,
July 5, 2005;
46(1):
106 - 112.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Takaya, C. Yuan, B. Chu, T. Saam, N. L. Polissar, G. P. Jarvik, C. Isaac, J. McDonough, C. Natiello, R. Small, et al.
Presence of Intraplaque Hemorrhage Stimulates Progression of Carotid Atherosclerotic Plaques: A High-Resolution Magnetic Resonance Imaging Study
Circulation,
May 31, 2005;
111(21):
2768 - 2775.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. R. Moreno and V. Fuster
New aspects in the pathogenesis of diabetic atherothrombosis
J. Am. Coll. Cardiol.,
December 21, 2004;
44(12):
2293 - 2300.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. R. Moreno and V. Fuster
The year in atherothrombosis
J. Am. Coll. Cardiol.,
December 7, 2004;
44(11):
2099 - 2110.
[Full Text]
[PDF]
|
|
|
|
